Catalio Capital Management

About

Catalio Capital Management is a global, multi-strategy specialist investor focused on breakthrough biomedical technology and healthcare companies. Its platform invests across company stages, sizes, and the capital structure through private, public-equity, and credit strategies.

Sectors

• Life Sciences
• Healthtech / Digital Health

Notable investments

• ArriVent BioPharma
• Dianthus Therapeutics
• Neumora Therapeutics
• Compass Pathways
• Paige

Investors

• George C. PetrocheilosCo-Founder & Managing Partner→
• R. Jacob Vogelstein, Ph.D.Co-Founder & Managing Partner→
• Tom BrooksPartner→
• John Henry Iucker, CFAPartner & Head of Credit→
• Ajay ManthaPartner→
• Isaac RoPartner→
• Ben SnedekerPartner & Head of Public Equities→
• Diamantis Xylas, M.D.Partner & Head of Research→
• Hai Yan, Ph.D.Partner→
• Pasquale ChiacchiariPrincipal & Head of Data Science→
• Matthew Hobson, Ph.D.Principal→
• Nicholas von Guionneau, M.D.Principal→
• Sean WangPrincipal→
• Will DenehyVice President, Europe→
• Vicky SostilioVice President, North America→
• Brian Malik, Ph.D.Senior Analyst→
• Constantine AlexosAnalyst→
• Trent MurphyAnalyst→
• Collin Spencer, Ph.D.Associate→
• David Stonko, M.D.Clinical Associate→
• Scott O’SullivanPrincipal & Head of Trading→

How to reach them

admin@cataliocapital.com